Publications by authors named "Alan Burnett"

Claim this Profile
A
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.
Farideh Miraki-Moud, Linda Ariza-McNaughton, Thinzar KoKo, Jad Othman, Randal Stronge, Alan Burnett

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Jad Othman, Nicola Potter, Sylvie D Freeman, Nicholas McCarthy, Jelena Jovanovic, Alan K Burnett

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.
Nicola Potter, Jelena Jovanovic, Adam Ivey, Jad Othman, Abin Thomas, Alan Burnett

Lancet Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Alan Burnett

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Alan Burnett

Blood· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Mhairi Copland, Cono Ariti, Ian F Thomas, Laura Upton, Mia Sydenham, Alan K Burnett

Br J Haematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of CEBPA mutational subgroups in adult AML.
Julia-Annabell Georgi, Sebastian Stasik, Michael Kramer, Manja Meggendorfer, Christoph Röllig, Alan Burnett

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Side-by-side comparison of published small molecule inhibitors against thapsigargin-induced store-operated Ca2+ entry in HEK293 cells.
Katherine Norman, Karen E Hemmings, Heba Shawer, Hollie L Appleby, Alan J Burnett

PLoS One· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
Francis Mussai, Carmela De Santo, Paul Cheng, Ian F Thomas, Cono Ariti, Alan K Burnett

Br J Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Megan Othus, Ian Thomas, Xu Wang, Cono Ariti, Priyanka Mehta, Alan K Burnett

Leuk Lymphoma· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Nigel H Russell, Robert K Hills, Lars Kjeldsen, Richard E Clark, Sahra Ali, Alan K Burnett

Br J Haematol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unified classification and risk-stratification in Acute Myeloid Leukemia.
Yanis Tazi, Juan E Arango-Ossa, Yangyu Zhou, Elsa Bernard, Ian Thomas, Alan K Burnett

Nat Commun· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
Nigel H Russell, Robert K Hills, Abin Thomas, Ian Thomas, Lars Kjeldsen, Alan K Burnett

Haematologica· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
Richard Dillon, Robert K Hills, Alan K Burnett, Nigel H Russell

Br J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy for isocitrate dehydrogenase 2 (IDH2) -mutant acute myeloid leukaemia.
David C Linch, Robert K Hills, Alan K Burnett, Nigel Russell, Rosemary E Gale

Br J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
Nigel Russell, Robert Hills, Lars Kjeldsen, Mike Dennis, Alan Burnett

Br J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Wei-Yu Lin, Sarah E Fordham, Eric Hungate, Nicola J Sunter, Claire Elstob, Alan K Burnett

Nat Commun· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Mike Dennis, Ian F Thomas, Cono Ariti, Laura Upton, Alan K Burnett

Blood Adv· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Wei-Yu Lin, Sarah E Fordham, Eric Hungate, Nicola J Sunter, Claire Elstob, Alan K Burnett

Nat Commun· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
David C Linch, Robert K Hills, Amanda Gilkes, Alan K Burnett, Nigel Russell

Leuk Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Mike Dennis, Alan Burnett, Robert Hills, Ian Thomas, Cono Ariti

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.
Alan K Burnett, Nigel H Russell, Robert K Hills, Stephen Knapper, Sylvie Freeman

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Sabine Kayser, Robert K Hills, Ralitsa Langova, Michael Kramer, Francesca Guijarro, Alan K Burnett

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Joanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, Ceri A Bygrave, Nader Omidvar, Alan K Burnett

Br J Haematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AML: New Drugs but New Challenges.
Alan Burnett, Richard Stone

Clin Lymphoma Myeloma Leuk· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis